Loading...
By Kelly Young
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
The FDA is examining the potential risks associated with brain deposits that may occur after repeated use of gadolinium-based contrast agents in magnetic resonance imaging.
Recent studies have found deposits of the agents in the brains of patients who have had at least four contrast MRI scans. Gadolinium-based contrast agents are largely eliminated via the kidneys, but small amounts of the agent may persist in the brain, even in patients with well-functioning kidneys.
It is not yet known if there are any adverse health effects associated with gadolinium accumulation in the brain. The agent already comes with a boxed warning about the risk for nephrogenic systemic fibrosis.
To reduce the risk to patients, the FDA says that healthcare providers should consider restricting use of gadolinium-based contrast agents to cases where the contrast is required to gain additional clinical data. Repetitive use of the agents is discouraged.
Comment
LINK(S):
FDA MedWatch safety alert (Free)
Background: Physician's First Watch coverage of boxed warning for gadolinium-based contrast agents (Free)